Management of the congenital solitary kidney: consensus recommendations of the Italian Society of Pediatric Nephrology

Claudio La Scola1 · Anita Ammenti2 · Cristina Bertulli1 · Monica Bodria3 · Milena Brugnara4 · Roberta Camilla5 · Valentina Capone6 · Luca Casadio7 · Roberto Chimenz8 · Maria L. Conte9 · Ester Conversano10 · Ciro Corrado11 · Stefano Guarino12 · Ilaria Luongo13 · Martino Marsciani14 · Pierluigi Marzuillo12 · Davide Meneghesso15 · Marco Pennesi16 · Fabrizio Pugliese16 · Sara Pusceddu17 · Elisa Ravaoli9 · Francesca Taroni6 · Gianluca Vergine9 · Licia Peruzzi5 · Giovanni Montini6,18

Received: 12 August 2021 / Revised: 3 March 2022 / Accepted: 4 March 2022 / Published online: 17 June 2022
© The Author(s) 2022

Abstract

Background In recent years, several studies have been published on the prognosis of children with congenital solitary kidney (CSK), with controversial results, and a worldwide consensus on management and follow-up is lacking. In this consensus statement, the Italian Society of Pediatric Nephrology summarizes the current knowledge on CSK and presents recommendations for its management, including diagnostic approach, nutritional and lifestyle habits, and follow-up.

Summary of the recommendations We recommend that any antenatal suspicion/diagnosis of CSK be confirmed by neonatal ultrasound (US), avoiding the routine use of further imaging if no other anomalies of kidney/urinary tract are detected. A CSK without additional abnormalities is expected to undergo compensatory enlargement, which should be assessed by US. We recommend that urinalysis, but not blood tests or genetic analysis, be routinely performed at diagnosis in infants and children showing compensatory enlargement of the CSK. Extrarenal malformations should be searched for, particularly genital tract malformations in females. An excessive protein and salt intake should be avoided, while sport participation should not be restricted. We recommend a lifelong follow-up, which should be tailored on risk stratification, as follows: low risk: CSK with compensatory enlargement, medium risk: CSK without compensatory enlargement and/or additional CAKUT, and high risk: decreased GFR and/or proteinuria, and/or hypertension. We recommend that in children at low-risk periodic US, urinalysis and BP measurement be performed; in those at medium risk, we recommend that serum creatinine also be measured; in high-risk children, the schedule has to be tailored according to kidney function and clinical data.

Keywords Congenital solitary kidney · Congenital anomalies of the kidney and urinary tract · Multicystic dysplastic kidney · Renal agenesis · Renal aplasia

Introduction and purpose

Congenital solitary kidney (CSK) occurs in approximately 1 in 2000 births and is associated with other congenital anomalies of the kidney and urinary tract (CAKUT) in about one in three cases [1, 2]. Several indications and protocols for follow-up have been issued [3–8] and, most recently, an overview of the clinical aspects and the long-term guidance for children with a congenital solitary functioning kidney has been published [9]. However, a worldwide consensus is still lacking. In this paper, we summarize the current knowledge on the subject and present the recommendations for the diagnosis, evaluation, and follow-up of CSK of the Italian Society of Pediatric Nephrology (SINePE), prepared by the CAKUT Working Group of the Society. Our recommendations are intended for use by all physicians dealing with neonates, infants, and children born with a solitary kidney, in or outside the hospital setting, and by specialists in pediatric and adult nephrology and urology. They can also be used for comparison with other available protocols and overviews.

Methods

The CAKUT working group of the SINePE, comprising 25 members (pediatric nephrologists and pediatricians), identified the questions and topics concerning CSK to be addressed
in the recommendations in an initial working group meeting. After the main topics were approved, members were divided into six sub-groups, each working on one or more questions; four pediatric nephrologists acted as a core leadership group (two as coordinators and writing committee, two as supervisors and revisers). Each sub-group performed a literature search and data extraction, using Excel sheets with specific fields to complete, and wrote the first draft of the answers to the assigned questions, grading evidence according to SORT criteria: strong (grade A), moderate (grade B), and weak (grade C) [10]. After this preliminary work, each draft and the relative recommendations were discussed in a further working group meeting, on the basis of which each group reviewed and completed their draft for the assigned questions. Then the writing committee drafted the whole manuscript, which was revised with the two supervisors and circulated to the whole working group for final approval. Finally, recommendations that were considered to be more controversial were submitted to the members of SINePE and of the CAKUT Working Group of the European Rare Kidney Disease Reference Network (ERKNet) by means of the Delphi method. There were 86 answers (57 from SINePE and 29 from ERKNet members). Recommendations that did not reach a consensus of at least 75% were revised by the writing committee and the supervisors, considering the suggestions made by the Delphi participants, and approved by the Working Group.

**Literature search**

The PICO (Patient or Population covered, Intervention, Comparator, Outcome) [11] framework was used to develop our search strategies and to formulate the questions for the consensus recommendations. Population was children with CSK; Interventions were 1 — diagnostic approach; 2 — evaluation of kidney function, signs of kidney damage, and blood pressure (BP); 3 — use of kidney protective medications, nutritional and lifestyle habits, and sports participation. Comparators were either the adoption or non-adoption of interventions for diagnosis, medical treatment, and follow-up. Outcomes were accuracy in the diagnosis of CSK, kidney function and BP, and quality of life. A Pub-Med search was performed from January 2000 to January 2021 using the following key words: congenital solitary kidney, unilateral renal agenesis, multicystic dysplastic kidney (MCDK), solitary kidney, renal dysplasia, and the following limits: humans, child, and English. The search retrieved 995 articles; from this list, we selected cohort studies, meta-analyses, and systematic reviews related to our above-mentioned interventions; no randomized clinical trials were available. One hundred and forty-nine articles were examined. Furthermore, a manual search was carried out, mainly using relevant references from the analyzed articles, which identified a further 21 articles, bringing the total to 170. From these, a final evaluation identified the 72 articles which were pertinent to the analyzed interventions and topics, and which provided appropriate data, and these are referenced in our consensus recommendations (Supplementary).

**Statistical analysis**

All statistical analyses were performed by the open-source software R (R Core Team (2021) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/).

In particular, weighted means, standard deviations, medians, and interquartile ranges (IQRs) were computed using the R package Hmisc (Frank E Harrell Jr, with contributions from Charles Dupont and many others. (2020) Hmisc: Harrell Miscellaneous. R package version 4.4–0. https://CRAN.R-project.org/package=Hmisc).

Weighted distributions were computed using the rates of patients in each study to the total number of patients as weights.

**Definition and classification**

Congenital solitary kidney is the anatomical or functional absence of one kidney from birth. The former is due to a complete failure of embryonic kidney formation (agenesis), the latter to extreme forms of dysplasia causing absence of function: aplasia and MCDK. This embryologic differentiation is usually possible when a CSK is suspected in the second trimester of pregnancy, mainly on the ultrasound (US) scan between the 18th and the 22nd weeks of gestation [12]. However, a dysplastic kidney may regress during fetal life; this is well known for MCDK, which can involute completely as early as the 29th week of pregnancy [8]. Therefore, the involuted dysplastic kidney becomes undetectable at US, and in the presence of an empty kidney fossa, it becomes difficult to ascertain whether it is due to agenesis, aplasia, or an involuted MCDK. In these cases, the exact classification is not possible, and the embryologic origin of the CSK has to be left undefined [7].

**Statements/recommendations:**

We recommend that CSK be classified as follows:

- **Agenesis:** absence of one kidney suspected on US scan between the 18th and 22nd weeks of gestation and confirmed postnatally.
- **Aplasia:** a rudimentary kidney suspected on US scan between the 18th and 22nd weeks of gestation, with relative function < 5% at 99mTc-dimercaptosuccinic acid scintigraphy (DMSA).
MCDK: multiple non-communicating cysts of various sizes within a lobulated renal contour, pelvis and parenchyma not being visible on US.

Undefined CSK: detection of an empty kidney fossa in the third trimester of pregnancy or after birth, with the differential diagnosis of agenesis, aplasia, or an involuted MCDK remaining uncertain (grade C).

What to do when a CSK is suspected/diagnosed by ultrasound prenatally?

The suspicion of a CSK can be raised by antenatal US screening, starting with the morphology scan at around 20 weeks of gestation; it can be substantiated by the detection of a compensatory enlargement of the CSK, which occurs in up to 88% of fetuses and can be demonstrated as early as the 20th week of gestation [13]. However, the anatomical absence of one kidney may not be detected in utero for a number of reasons: the adrenal gland can fill the kidney fossa and may be mistaken for the kidney; late in the second or in the third trimester, the retroperitoneal colon can suggest the presence of a kidney; an initially visible dysplastic kidney may regress to the point of becoming undetectable by US (approximately 5% of MCDKs) [8, 12]. Data from European collaborative registries on 709,030 births [14] showed that unilateral kidney agenesis (UKA) was correctly detected by prenatal US in 62% of cases, if isolated, and in 80% of cases when associated with other malformations; in an Italian cohort, a CSK was correctly identified prenatally in 62% of patients [7]. Antenatal US has other caveats: the kidney fossa may be empty because of kidney ectopia, which may not be identified, and the prenatal distinction between MCDK and severe hydrenephrosis may be difficult: in a group of patients with MCDK, 30% (15/50) were erroneously diagnosed with hydrenephrosis [15].

A prenatally identified CSK is diagnosed as an isolated anomaly in approximately two thirds of cases, but is associated with multiple malformations (syndromic or non-syndromic), in about a third of patients [14]. For this reason, if a CSK is described, it is important that a specialized US scan of the whole fetus be performed [12]. If the CSK is isolated, we believe that standard obstetric follow-up is warranted. In the presence of additional fetal structural malformations, the risk of genetic abnormalities is increased, and may surpass 50% for some associations [16]. In these cases, chorionic villus sampling or amniocentesis with chromosomal microarray/karyotyping should be offered [16].

Statements/recommendations:

1. We recommend that a specialized US examination of the whole fetus be performed when a CSK is diagnosed prenatally (grade B).

2. We recommend that in fetuses with a diagnosis of CSK as an isolated malformation no diagnostic procedure other than standard obstetric follow-up be performed (grade C).

3. We recommend that in fetuses with a diagnosis of CSK associated with extrarenal malformations, chorionic villus sampling or amniocentesis with chromosomal microarray/karyotyping should be offered (grade B).

4. We recommend that any antenatal suspicion/diagnosis of CSK or detection of abnormal kidney or urinary tract morphology be confirmed by neonatal US (grade B).

How should a CSK be confirmed postnatally?

The prenatal suspicion/detection of a CSK has to be substantiated by a neonatal US scan.

The postnatal US report should always describe kidney length, echogenicity and parenchymal thickness, the features of the calyces, and the antero-posterior diameter of the renal pelvis where it exits the parenchyma. Other important characteristics are the maximal ureteric diameter, if visible, bladder wall thickness and, if possible, pre-void and post-void bladder volume.

Although scintigraphy is the gold standard for confirming the functional absence of a kidney, advances in US technology mean that nuclear scans are not necessary in most cases, thus avoiding radiation exposure. In a study involving 128 CSK patients (agenesis 75, MCDK 53) confirmed by nuclear scan, neonatal US detected CSK in the vast majority of patients; however, it missed 8.6% of cases, which were all MCDK [17]. In that study, neonatal US had a specificity of 100% and a sensitivity of 92.1%; sensitivity was 100% for agenesis and aplasia and 82.8% for MCDK. The positive and negative predictive values were 100% and 99.9%, respectively. In another study, US correctly diagnosed a CSK, as confirmed by nuclear scanning, in 24/25 infants; in 1 patient, US suggested a pelvic kidney but repeat US was negative, as was the DMSA scan [18]. Whittam et al. verified the absence of function in 84/84 MCDK patients with a nuclear scan, previously diagnosed by postnatal US [15]. The possibility that an ectopic kidney may be missed by US is not substantiated by the above-mentioned literature; moreover, the presence of a rudimentary ectopic kidney would be irrelevant for management and follow-up. For these reasons, we believe that a postnatal US scan performed by an experienced pediatric radiologist is, in most cases, sufficient for the definitive diagnosis of a CSK. In questionable cases and/or if US cannot distinguish between an MCDK and severe hydrenephrosis, a more extensive imaging work-up (mercaptoacetyltriglycine scintigraphy or magnetic resonance urography) has been suggested [19].
**Statements/recommendations:**

1. For the definitive diagnosis of CSK, a neonatal US performed by an experienced pediatric radiologist is sufficient in most cases (grade B).
2. We do not recommend the routine use of scintigraphy to confirm the anatomical or functional absence of a kidney (grade B).
3. Further imaging is recommended in the event of the uncertain diagnosis of a rudimentary kidney (DMSA) or of a doubtful differential diagnosis between MCDK and severe hydronephrosis (mercaptoacetyltriglycine scintigraphy or magnetic resonance urography) (grade C).

**What further imaging is required when a CSK is confirmed?**

Having diagnosed the anatomical or functional absence of one kidney, the next step is to exclude an anomaly of the contralateral urinary tract, as about one in three patients has additional CAKUT [1, 2]. While US can raise the suspicion of many anomalies of the urinary tract (i.e., pelvi-ureteric junction obstruction, megaureter, duplex system), it has a low predictive value for the presence of vesicoureteral reflux (VUR) [20]. Thus, three main questions have to be addressed:

- a. Is the CSK normal at US?
- b. Should imaging to detect VUR be performed routinely?
- c. When should further imaging for associated uropathies be performed?

**a) Is the CSK a normal kidney?**

A CSK without additional abnormalities is expected to undergo compensatory growth. Whether this enlargement is due to the hypertrophy of existing nephrons or to an increase in the number of nephrons formed in utero, leading to hyperplasia, is still debated [7, 21]. Compensatory enlargement can start during gestation, and can be detected by current US techniques sometimes as early as the 20th week [13]. However, compensatory growth is often established in the first year of life, or beyond in some cases [22, 23]. Once a CSK has undergone compensatory enlargement, its length/size does not subsequently regress [22]. To evaluate if compensatory growth of the CSK is taking place, US measurements of kidney length can be used, comparing them with normative data. At present, nomograms constructed from US measurements to assess kidney length in children with two kidneys [24–26] are used. Compensatory enlargement of the CSK in children is defined either in relation to age (length ≥ 2 or >2.5 SD) [23, 27–33], or in relation to height (≥ 95th percentile) [7, 17, 22, 34–37], while in adults, the expected value is ≥ 120 mm [38, 39]. As there is a wide variability of physical growth with age, we believe that relating kidney length to height rather than to age is more appropriate. For that purpose, we suggest using the nomograms published by Dinkel et al. (Figure 1) [25]. Alternatively, the web-based tool published by Chen et al., which requires multiple demographic variables, could be used (available at: https://www.preved.sunysb.edu/jjc/MrNomogram/default2.aspx) [26]. However, it should be remembered that in conditions which distort normal kidney anatomy, such as hydronephrosis, a duplex collecting system, or an ectopic kidney, kidney length may not accurately reflect the compensatory enlargement of the parenchyma: in these cases, the available nomograms of parenchymal area for CSK should be considered [27]. Furthermore, it is important to bear in mind that the rate of kidney growth is most rapid during the first 2 years of life and that it slows down between 2 and 5 years, after which kidney length increases by only 2–3 mm per year throughout adolescence [40].

We believe that a CSK which does not fulfill the parameters outlined in Box 1 should be considered abnormal.

**Box 1 Opinion-based definition of a normal ultrasound for congenital solitary kidney.**

| US parameter | Needed description | Normal findings | Timing |
|--------------|--------------------|-----------------|--------|
| Kidney length | Bipolar diameter in millimeters | >50th percentile | Until 2 years of life |
|              |                    | ≥95th percentile | After 2 years of life |
| Parenchyma   | Thickness          | Normal           | Any time |
|              | Ecchogenicity      | Normal           | Any time |
|              | Corticomedullary differentiation | Normal | Any time |
|              | Cysts              | Absent           | Any time |
| Renal pelvis | Antero-posterior diameter in millimeters | ≤10 mm | >48 h of life |
| Calices      | Dilatation         | Absent           | Any time |
| Ureter       | Dilatation         | Absent           | Any time |
| Bladder      | Wall thickness     | Normal           | Any time |
|              | Ureterocele        | Absent           | Any time |

**Statements/recommendations:**

1. A CSK without additional abnormalities is expected to undergo compensatory growth (grade B).
2. We recommend measuring the US length of a CSK at diagnosis and at each US during follow-up (grade C).
3. We recommend that the length of the CSK be evaluated with nomograms, relating kidney length to body height (grade C).

4. If the kidney shows abnormalities in morphology or position (i.e., it is hydronephrotic or ectopic), length measurements may not reflect parenchymal enlargement; in these cases, measuring the parenchymal area should be considered (grade C).

5. We recommend that the term compensatory enlargement, rather than compensatory hypertrophy, be used as the exact mechanism leading to the increased growth of a CSK is still unknown (grade C).

Fig. 1 Sonographical growth charts for kidney length related to height (5th, 50th, and 95th percentiles). Reproduced from Dinkel et al. [25], used with permission.
6. We recommend waiting until 2 years of age to establish the absence of compensatory enlargement (grade C).

b) Should imaging to detect VUR be performed routinely?

Among the urologic abnormalities associated with CSK, vesicoureteral reflux is the most common [1, 2, 7, 31, 41]. Two systematic reviews involving over 5600 patients with MCDK or UKA, 2874 having been examined for the presence of VUR, showed an overall rate of about one in five patients [1, 2]. However, severe VUR (i.e., grades III–V according to the International Reflux Study classification) appears to be infrequent, having been documented in 9% of children with CSK overall in recent series [1, 7, 31, 41–43] (Table 1).

Ultrasound has a low predictive value for the presence of VUR as it often yields normal results in children with low grade and even in some with high grade VUR [20, 44]. Therefore, further imaging procedures are needed to detect VUR, fluoroscopic contrast voiding cystourethrography (VCUG) being the standard. However, from a clinical point of view, low grade VUR is increasingly recognized as negligible, in terms of both the rate of UTI and the risk of kidney scarring, while the role severe VUR plays in clinical outcome is still debated, as conclusive evidence is lacking [45]. Multiple studies have demonstrated a low incidence of clinically significant VUR in children with MCDK and a normal contralateral kidney and bladder on US [41]; furthermore, Brown et al. found that knowledge of VUR in 77 children with MCDK screened by VCUG did not change patient management [43]. Accordingly, we believe that routine screening for VUR is not necessary in the presence of a normal CSK on US (Box 1). In this context, in our opinion, an isolated dilatation of the renal pelvis ≤ 10 mm does not represent an indication for VCUG. On the other hand, it has been shown that in children with an abnormal CSK on US, the probability of a high grade VUR is elevated [41, 46]. In the risk analysis performed by Blachman-Braun et al., a significant association (odds ratio = 7.73; 95%CI: 1.43–41.81; p = 0.018) between abnormal CSK on US (defined as abnormal contralateral kidney, presence of hydronephrosis, duplex configuration, ureterocele, hydroureter, or urethropelvic thickening) and severe VUR was demonstrated in 156 MCDK patients [41]. For this reason, we believe that VCUG should be performed when US abnormalities of the CSK or urinary tract are reported (see Box 1).

Statements/Recommendations:

1. In children with a normal CSK and urinary tract on US (Box 1), routine imaging to rule out the presence of VUR is not recommended (grade B).
2. We believe that VCUG should be performed when abnormalities of the CSK or urinary tract are reported on US (see Box 1) (Grade C).

c) When should further imaging for associated uropathies be performed?

In general, if a urinary tract anomaly associated with CSK is detected on US, further imaging should be performed as

Table 1  Reported prevalence of associated uropathies in children with CSK

| Author, year     | Number of pts | CSK type (%) | Associated CAKUT, % | Total VUR, % | VUR grades III–V, % | UPJO, % | VUJO, % |
|------------------|---------------|--------------|---------------------|--------------|---------------------|---------|---------|
| Schreuder M. (2009) [1] | 3557          | MCDK (100)   | 31.3 (of 2415 pts)  | 15 (of 2104 pts) | 8 | 4.8 (of 2159 pts) | NR |
| Westland R. (2013) [2] | 1093          | UKA (100)    | 32                   | 24 (of 770 pts) | NR | 6 (of 615 pts) | 7 (of 605 pts) |
| La Scola C. (2016) [7] | 146           | MCDK (38), UKA (29), UKAP (16), Undefined (18) | 21 | 11.5 | 10 | 2 | 3 |
| Ross I. (2015) [42] | 138           | MCDK (63), UKA (37) | NR | 36 | 17 | NR | NR |
| Marzuillo P. (2017) [31] | 322          | MCDK (48), UKA (52) | 14.6 | 9.3 | 5.6 | 0.3 | 4 |
| Brown C. (2019) [43] | 165           | MCDK (100)   | 33                   | 17 (of 77 pts) | NR | NR | NR |
| Blachman-Braun R. (2020) [41] | 156 | MCDK (100) | NR | 16 | 6 | NR | NR |

*Previous works not analyzed as present in the two metaanalyses

Legend: Pts patients, CSK congenital solitary kidney, CAKUT congenital anomalies of kidney and urinary tract, VUR vesicoureteral reflux, UPJO ureteropelvic junction obstruction, VUJO vesicoureteral junction obstruction, MCDK multicystic dysplastic kidney, UKA unilateral kidney agenesis, UKAP unilateral kidney aplasia, NR not reported
recommended in children with two kidneys, particularly after a febrile UTI [44] and if obstruction is suspected. Special attention should be paid to obstructive uropathies of the CSK, which may be severe enough to cause acute kidney failure [47].

**Statements/recommendations:**

1. If a urinary tract anomaly associated with CSK is detected on US, further imaging should be performed, as indicated in children with two kidneys (grade C).
2. We recommend that special attention be paid to the diagnosis of an obstructive uropathy which, if severe, may cause acute kidney failure in a solitary kidney (grade C).

### Are laboratory tests necessary at diagnosis?

To date, several opinion-based recommendations on the type and timing of laboratory tests in children with CSK have been published [5–7, 9]. In each of these, laboratory testing (in particular, albuminuria or proteinuria, and serum creatinine) is foreseen, with different scheduling based on the presence or absence of an ipsilateral CAKUT. La Scola et al. first introduced the concept of timing based also on kidney length/size and proposed less intensive laboratory assessments for children with an adequate kidney length/size [7]. Poggiali et al. used a prediction model, including neonatal plasma creatinine, kidney length, and history of recurrent UTIs, which enabled the identification of a subgroup of patients with an increased risk of kidney damage, hypertension and/or reduced glomerular filtration rate (GFR) over time [48]. In a more recent paper on the clinical management of children with CSK, it was reported that none of the 46 children with a kidney size of >2 SDs above the mean for age (for an individual with two kidneys) had a reduced kidney function within the first year of life. Therefore, the authors suggested that in the absence of other clinical indications, it seems reasonable to refrain from an initial creatinine measurement in CSK patients with compensatory hypertrophy [9]. It must also be underlined that the above-mentioned opinion-based recommendations were derived from studies carried out in specialized units, where patients are likely to be the most severely affected, and so selection bias may have played a part. We recommend performing urinalysis, to rule out proteinuria, but not routine blood tests, at diagnosis in infants and children with normal US measurements for CSK, as delineated in Box 1 (grade C).

When and how should extra-renal malformations be searched for?

Extra-renal malformations can be associated with CSK, with a prevalence described between 6 and 31% in hospital-based series [1, 2, 7, 31, 34, 50] (Table 2). In the aforementioned systematic reviews, extra-renal malformations were described in approximately 15% of 1340 subjects with MCDK [1] and in 31% of 709 subjects with UKA [2]. These malformations occurred as part of specific multi-organ syndromes in up to 10% of patients [7, 31, 34]. The most frequently described extra-renal malformations involve the heart, the gastrointestinal tract, and the musculoskeletal and genital apparatuses. Therefore, a careful clinical examination must always be performed in subjects with CSK, both at diagnosis and during follow-up, in order to detect signs of extra-renal malformations needing further work-up. If extra-renal malformations are detected, the possible presence of a syndrome (Table 3) and the need for genetic counseling/analysis have to be considered [3]. An association which calls for special attention is that between CSK and genital malformations [2, 51–53]. This association, although occasionally present in males (seminal vesicle hypoplasia and absence of the vas deferens), is more common in females: female tract malformations were described in 11% of 502 patients with UKA in the meta-analysis performed by Westland [2]. They may include uterine and vaginal agenesis, uterine duplicity (didelphys, bicornuate or septate uterus), obstructed or blind hemivagina, monolateral ovarian agenesis, and Gartner duct pseudocyst. These malformations are frequently linked to syndromes (Table 3). As prenatal US is not a reliable method for genital malformation screening, and as some of these conditions can be asymptomatic during childhood, their detection is often delayed until after menarche, when serious complications caused by obstructive anomalies can arise [51]. For this reason, an abdominopelvic US must be performed in all girls with a CSK between thelarche and menarche, to exclude genital abnormalities [51].

**Statements/recommendations:**

1. We recommend that a careful clinical examination be performed at diagnosis and during follow-up, to detect
signs of extra-renal malformations needing further work-up (grade C).

2. In all girls with a CSK, we recommend screening for genital malformations by means of an abdominopelvic US, between thelarche and menarche (grade B).

3. If extra-renal malformations are detected, the possible presence of a syndrome and the need for genetic analysis and/or counseling have to be considered (grade A).

Is it necessary to perform genetic analysis in non-syndromic forms of CSK?

Genetic studies specifically focused on CSK are rare, as this malformation is usually studied in the context of CAKUT. At present, from a genetic point of view, the cause remains speculative in approximately 80% of CAKUT cases, with several studies supporting a multifactorial pathogenesis [54]. In a recent study on 86 patients with UKA, 9 subjects (10.5%) showed pathogenic mutations in seven different genes [55]. Ishiwa et al., in a study on 66 patients with severe CAKUT (i.e., associated to extreme forms of dysplasia with bilateral kidney lesions, extrarenal complications, or a family history of kidney disease), detected mutations in 10/33 subjects (30%) in whom MCDK or kidney aplasia were associated with a severe malformation of the contralateral CSK [56]. In this series, the detection rate of genetic anomalies was significantly higher in subjects with bilateral kidney lesions than in those with a syndromic CAKUT or a family history of renal malformations. The most frequent genetic anomalies concerned $HNF1B$ and $PAX2$ [56]. Van der Ven et al. performed whole-exome sequencing in 232 families in which 319 subjects were affected by CAKUT. In 29/232 families, a mutation in known genes for CAKUT was detected, and in 10/29, the corresponding clinical phenotype showed the presence of UKA or MCDK [57].

Thus, at present, the complex underlying genetic mechanisms of CAKUT and CSK do not allow for the establishment of a common diagnostic approach for all patients, and in each case, the most indicated test and the diagnostic yield should be considered [58], taking into account that in subjects with bilateral kidney lesions, the detection rate of genetic anomalies is higher than in isolated CSK and that a search for genetic anomalies seems reasonable in families with recurrent cases of CAKUT.

Statements/recommendations:

1. We do not recommend genetic counseling/analysis in children with an isolated and sporadic CSK (grade C).
We suggest that genetic counseling be offered to children with a CSK and an ipsilateral CAKUT and/or a family history of CAKUT (grade C).

**Risk of decreasing glomerular filtration rate and of kidney damage (proteinuria and hypertension) over time**

In spite of the high variability of nephron numbers in the general population [59], nephron number is likely to be lower in subjects with CSK than in those with two kidneys [60]. When there is a reduced number of functioning nephrons, compensatory physiological and biochemical adaptations occur. In animals with extensive kidney ablation, these adaptations produce glomerular overload and hyperfiltration, resulting in proteinuria, glomerulosclerosis, higher rates of hypertension, and decreasing GFR [61]. In humans, an extensive debate on the prognosis of CSK exists, and some risk factors have been demonstrated to have a negative impact on outcome. Therefore, from a clinical perspective, the challenge is to identify patients at increased risk of kidney damage and GFR reduction, in order to tailor their follow-up accordingly.

Three main questions have to be addressed:

a) What is the risk of decreasing GFR over time?
b) What is the risk of developing proteinuria?
c) What is the risk of developing hypertension?

**a) Is a child with CSK at risk of decreasing glomerular filtration rate?**

Studies analyzing kidney function over time in patients with CSK have described a variable prevalence of reduced function both in children [4, 7, 17, 22, 23, 30, 31, 33, 34, 48, 62–66] and in adults [38, 39, 67–69] (Table 4). This high variability was influenced by different inclusion criteria, follow-up periods, and outcome measures: in particular, in some studies, the outcome was GFR < 90 ml/min/1.73 m², in others < 60 ml/min/1.73 m². In addition, many studies were performed in referral hospitals, possibly selecting patients with more serious conditions. In Table 5, we report the calculated weighted means, standard deviations, weighted medians, and IQRs for the outcome GFR reduction, separately for children and adults. Moreover, a stratified analysis for pediatric cohorts according to the GFR threshold (< 90 ml/min/1.73 m² in 9 series, < 60 ml/min/1.73 m² in 4...
In twelve of these studies, nine involving children [7, 17, 23, 31, 33, 34, 48, 64, 65] and three involving adults [38, 39, 69] (Table 6). The two most frequently analyzed risk factors in children were kidney length and the presence of an associated ipsilateral CAKUT. Compensatory enlargement has been described as a key parameter for normal kidney function [7] and, in general, subjects with a compensatory enlargement of the CSK and without ipsilateral CAKUT have a favorable outcome [7, 23, 31]. The strongest predictor of unfavorable outcome is the absence of compensatory enlargement of the CSK [7, 23, 38, 48, 64]. The presence of an ipsilateral CAKUT has also been described as a risk factor; however, it lost its significance at multivariate analysis in some cohorts [7, 17, 48]. A risk analysis of different CAKUT on the outcome in children with CSK is not available. The role of prematurity and low birth weight, which may impact nephrogenesis in terms of reduced nephron number [76], has also been analyzed in several studies [7, 17, 31, 48, 64]. The impact on kidney function in CSK appears limited in childhood, no studies being available in adults. Urinary tract infections in association with CSK could represent a risk factor, particularly if the infections are recurrent [7, 48, 64]. At present, a role for other studied risk factors does not appear to be relevant in the decline of GFR in children with CSK (Table 6). In adults, proteinuria and hypertension have been described as significant risk factors for decreased GFR [38, 39].

Based on the analyzed cohort studies (Tables 4 and 5) and on the reported risk factor analysis for GFR reduction (Table 6), we observe that two CSK populations exist. The first, in which there is no compensatory enlargement of the CSK and/or an additional ipsilateral CAKUT is present, is at increased risk for GFR reduction and chronic kidney disease (CKD) progression; the second, showing compensatory enlargement of the CSK and the absence of ipsilateral CAKUT, has a lesser risk for GFR reduction and CKD progression.

### Statements/recommendations:

1. Children without compensatory enlargement of the CSK and/or additional ipsilateral CAKUT are at risk of GFR reduction and CKD progression (grade B).

2. Children showing a CSK with compensatory enlargement and the absence of ipsilateral CAKUT are at a lesser risk of GFR reduction and ipsilateral CAKUT progression (grade B).

### b) Is a child with CSK at risk of proteinuria?

Various studies evaluating kidney damage in patients with CSK have assessed the presence of proteinuria [7, 22, 23, 31, 33, 34, 48, 64, 67–69] and/or albuminuria [4, 17, 29, 33, 38, 62, 63, 65]. These studies, which had different inclusion criteria and follow-up periods, showed a variable prevalence of proteinuria/albuminuria (Table 4), both in children [4, 7, 17, 22, 23, 29, 31, 33, 34, 48, 62–65] and in adults [38, 39, 67–69]. In Table 5, we report the calculated weighted means, standard deviations, weighted medians, and IQRs for the prevalence of proteinuria/albuminuria, separately for children and adults. On the whole, the prevalence is higher than in the general pediatric population, in which it ranges between 0.0012 and 0.22% [77, 78]. The prevalence of albuminuria ranged between 3 and 24% in children [4, 17, 29, 33, 62, 63, 65] and was found in 48% of adults in one series [38]. In these series, the presence of proteinuria/albuminuria is reported as a categorical variable, so that their exact amount cannot be inferred. Proteinuria has been found to be higher in patients with ipsilateral CAKUT associated with CSK [17, 33, 48, 65]. Only one study evaluated the absence of kidney enlargement, baseline creatinine, and recurrent UTIs as risk factors for proteinuria and a positive correlation was found, while no correlation was found with low birth weight [48]. No studies have evaluated the role of proteinuria as a risk factor for GFR reduction in children with CSK. The use of antiproteinuric medications has only been reported in a few studies [33, 38, 64, 65]; however, no data on efficacy and safety are available.

### Statements/recommendations:

1. The prevalence of proteinuria in children with a CSK is higher than in the normal pediatric population (Grade B).

2. Evaluation of proteinuria is warranted in every child with a CSK (grade B).

### c) Is a child with CSK at risk of developing hypertension?

A variable prevalence of hypertension has been documented by office BP recordings in children with CSK (Table 4) [4, 7, 17, 22, 23, 29–31, 33, 34, 48, 62–66]. In Table 5, we report the calculated weighted means, standard deviations, weighted medians, and IQRs for the prevalence of hypertension. The prevalence of hypertension in many cohorts was similar [4, 7, 17, 34, 48, 63] or even lower [22, 23, 30, 31].
| Author, year | Age | Compensatory enlargement* | Ipsilateral CAKUT | Kidney injury | GFR reduction | Proteinuria/albuminuria | Hypertension |
|--------------|-----|---------------------------|-------------------|--------------|---------------|-----------------------|-------------|
| Weinstein A. (2008) [22] | C 80 | 80% | NR | eGFR < 90 ml/min/1.73 m² | 0/23 | Dipstick > +1 | 0/20 | > 95th pct | 0/31 (0) |
| Vu K. H. (2008) [44] | C 56 | "normal kidneys" | None | eGFR < 90 ml/min/1.73 m² | 6/56 (10.7) | ACR > 0.25 mg/ml | 4/52 (7.7) | > 95th pct | 3/56 (5.3) |
| Abou Jaoudé P. (2011) [62] | C 44 | "normal kidneys" | None | mGFR < 90 ml/min/1.73 m² | 5/44 (11.4%) | UAlb/UCr > 2 mg/mmol | 8/44 (18) | > 95th pct | 1/44 (2.2) |
| Mansoor O. (2011) [34] | C 121 | 74% (of 101 patients) | CooperH | eGFR < 90 ml/min/1.73 m² | 8/82 (9.7) | UPr/UCr ≥ 0.2 mg/ml | 14/82 (17) | > 95th pct | 6/86 (7) |
| Hayes W. N. (2012) [30] | C 323 | 97% | CooperH | mGFR < 90 ml/min/1.73 m² | 33/76 (43) | NR | 0/94 (0) | |
| Stefanowicz J. (2012) [63] | C 17 | NR | None | eGFR < 90 ml/min/1.73 m² | 0/17 | ACR > 30 mg/g | 4/17 (24) | > 95th pct | 1/17 (6) |
| Westland R. (2013) [64]** | C 223 | NR | None | mGFR < 90 ml/min/1.73 m² | 68/223 (31) | UPr/UCr > 0.2 mg/ml (> 0.5 if < 2 yrs) or ACR > 30 mg/g | 29/223 (13) | > 95th pct | 49/223 (22) |
| Kolvek G. (2014) [65] | C 27 | NR | None | eGFR < 90 ml/min/1.73 m² | 9/27 (33.3) | ≥ 300 mg/24 h | 2/27 (7.4) | > 95th pct | 5/27 (18) |
| Siomou E. (2014) [66] | C 38 | 100% | 0 | eGFR < 90 ml/min/1.73 m² | 17/38 (44.7) | NR | 4/38 (11) | |
| La Scola C. (2016) [7] | C 146 | 65% | 21% | mGFR < 90 ml/min/1.73 m² | 18/146 (12) | UPr/UCr > 0.2 mg/ml (> 0.5 if < 2 yrs) | 5/134 (4) | > 95th pct | 6/121 (5) |
| Marzullo P. (2017) [31]*** | C 322 | 74% | 15% | eGFR < 90 ml/min/1.73 m² | 12/306 (3.9) | UPr/UCr > 0.2 mg/ml (> 0.5 if < 2 yrs) | 11/306 (3.6) | > 95th pct | 2/306 (0.6) |
| Urisarri A. (2018) [17] | C 128 | 64% | 35% | mGFR < 90 ml/min/1.73 m² | 3/128 (2.3) | ACR 30 mg/g | 4/128 (3) | > 95th pct | 6/128 (4.6) |
| Poggiali I. (2019) [48] | C 162 | NR | None | eGFR < 60 ml/min/1.73 m² | 18/162 (11.1) | UPr/UCr > 0.2 mg/ml or > 150 mg/day | 10/162 (6.2) | > 95th pct | 11/162 (6.8) |
Table 4 (continued)

| Author, year | Age | N  | Compensatory enlargement* | Ipsilateral CAKUT | Kidney injury Definition | Outcome N (%) | GFR reduction Evaluated as | Outcome N (%) | Proteinuria/albuminuria Evaluated as | Outcome N (%) | Hypertension Definition | Outcome N (%) |
|--------------|-----|----|----------------------------|-------------------|--------------------------|---------------|---------------------------|---------------|-------------------------------------|---------------|-------------------------|---------------|
| Sanna Cherchi S. (2009) [68] | A   | 111 | NR                         | NR                | eGFR < 15 ml/min/1.73 m² | 23/111 (21)   | > 1 g/day                | 5/111 (4.5)   | NR                                  | 3/111 (2.7)   |
| Argueso L. R. (1992) [67]    | A   | 157 | 100%                       | NR                | mGFR < 90 ml/min/1.73 m² | 4/32 (13)     | > 150 mg                  | 7/37 (19)     | > 140/95 mmHg and/or T | 22/47 (47)    |
| Wang Y. (2010) [38]          | A   | 65  | NR                         | NR                | mGFR < 60 ml/min/1.73 m² | 25/65 (38)    | ACR > 10 mg/ mmol or RPM   | 31/65 (48)    | > 140/90 mmHg and/or T | 24/65 (36)    |
| Basturk T. (2015) [39]       | A   | 31  | NR                         | NR                | sCr > 1.4 mg/dl in men or > 1.3 mg/dl in women or eGFR < 60 ml/min/1.73 m² or Proteinuria ≥ 300 mg/day | 17/31 (55) | mGFR < 60 ml/min/1.73 m² | 14/31 (45) | UPr ≥ 300 mg/day | 12/31 (39) | NR                                  | 21/31 (67)    |
| Xu Q. (2019) [69]            | A   | 118 | NR                         | NR                | Hy, Proteinuria and eGFR < 60 ml/min/1.73 m² | 62/118 (53) | eGFR < 60 ml/min/1.73 m² | 30/118 (25.4) | > 150 mg/day | 49/114 (43) | ≥ 140/90 mmHg | 38/118 (32.2) |

*Kidney length ≥ 2SD for age or ≥ 95th percentile for height; **includes also cohorts described in references 29 and 33; ***includes also patients described in reference 23

Legend: CAKUT congenital anomalies of kidney and urinary tract, C children, A adults, Hy hypertension, eGFR estimated glomerular filtration rate, mGFR measured glomerular filtration rate, UAlb urine albumin, UPr urine protein, UCr urine creatinine, ACR albumin creatinine ratio, NR not reported, RPM renoprotective medication, T therapy
1. Statements/Recommendations:

In these 10 studies had a GFR > 60 ml/min/1.73 m², while approximately 22% of them had elevated office BP readings before ABPM. At ABPM, mean BP values were generally within the normal range, but were higher in children with CSK versus healthy controls [28, 71, 73, 75, 85] or versus children with other CAKUT [37]. The prevalence of ABPM-hypertension was reported in 8 out of 10 studies [28, 37, 70–75] (Table 7), with weighted mean prevalence of 27.9 ± 9.7% (Table 5); in the cohort of Lubrano et al., 82% of hypertensive children had kidney scars [74]. White coat hypertension was reported in six studies and was detected in a variable percentage of children (0–26%) [28, 37, 70, 72, 74, 75]. The weighted mean prevalence of masked hypertension, available from six studies, was 14.3 ± 11.9% (Table 5) [28, 37, 70, 72, 74, 75]. It has to be underlined that the high proportion of masked hypertension cases could have been overestimated, as it has previously been shown that many patients with masked hypertension become normotensive at a second ABPM [86]. On the other hand, the identification of masked hypertension is considered important, as some studies have shown a similar left ventricular mass index in subjects with either masked or sustained hypertension [81]. However, no studies relating ABPM levels to outcomes such as myocardial infarction or stroke are currently available for the pediatric population [81].

We recommend that ABPM be performed in children with CSK and office BP > 95th percentile to determine whether sustained hypertension or white coat hypertension exists. As

### Table 5  Weighted distribution of outcomes calculated from the cohorts reported in Tables 4 and 7

| Outcome                  | Population                                      | N. of cohorts | Mean ± sd  | Median (IQR) |
|--------------------------|-------------------------------------------------|---------------|------------|--------------|
| GFR reduction            | Pediatric cohorts [4, 7, 17, 22, 30, 31, 34, 48, 62–66] | 13            | 8.7 ± 12.3% | 5.6% (8.8%)  |
| GFR reduction < 90 ml/min/1.73 m² | Pediatric cohorts [4, 7, 22, 30, 31, 34, 62, 63, 66] | 9             | 11.5 ± 15.9% | 10.7% (11.0%) |
| GFR reduction < 60 ml/min/1.73 m² | Pediatric cohorts [17, 48, 64, 65] | 4             | 4.4 ± 2.3%   | 4.8% (2.9%)   |
| GFR reduction            | Adult cohorts [38, 39, 67–69]                    | 5             | 26.9 ± 10.6% | 25.4% (17.7%) |
| Proteinuria/albuminuria  | Pediatric cohorts [4, 7, 17, 22, 31, 34, 48, 62–65] | 11            | 7.6 ± 5.8%   | 6.2% (9.4%)   |
| Hypertension             | Pediatric cohorts [4, 7, 17, 22, 30, 31, 34, 48, 62–66] | 13            | 7.1 ± 8.1%   | 5.0% (6.3%)   |
| ABPM hypertension        | Pediatric cohorts [28, 37, 70–75]               | 8             | 28.0 ± 9.7%  | 31.1% (13.0%) |
| ABPM masked hypertension | Pediatric cohorts [28, 37, 70, 72, 74, 75]        | 6             | 14.3 ± 11.9% | 19.9% (19.4%) |

In square brackets: references

Legend: GFR glomerular filtration rate, ABPM ambulatory blood pressure monitoring

2. We recommend that office BP be measured in every child with a CSK (grade B).

3. At present, no clear risk factors for hypertension in children with a CSK have been demonstrated (grade C).

### Should ambulatory blood pressure monitoring be performed in children with CSK?

Ambulatory blood pressure monitoring (ABPM) is increasingly recognized as a useful tool in the diagnosis of hypertension, particularly because ABPM alone is able to detect white coat hypertension and masked hypertension [81, 82]; reference data for children are available from the age of 5 years [83, 84]. Ten studies evaluated BP by ABPM in a total number of 379 children with CSK [28, 32, 37, 70–75, 85] (Table 7). Five studies reported data on kidney length for a total of 136 patients and about 86% presented compensatory enlargement [28, 32, 70, 72, 85]. Six studies reported data on ipsilateral CAKUT, which were present in a minority of patients [28, 37, 70, 71, 75, 85], while in the study by Lubrano et al., 24 out of 38 had kidney scars [74]. Most of the children in these 10 studies had a GFR > 60 ml/min/1.73 m², while approximately 22% of them had elevated office BP readings before ABPM. At ABPM, mean BP values were generally within the normal range, but were higher in children with CSK versus healthy controls [28, 71, 73, 75, 85] or versus children with other CAKUT [37]. The prevalence of ABPM-hypertension was reported in 8 out of 10 studies [28, 37, 70–75] (Table 7), with weighted mean prevalence of 27.9 ± 9.7% (Table 5); in the cohort of Lubrano et al., 82% of hypertensive children had kidney scars [74]. White coat hypertension was reported in six studies and was detected in a variable percentage of children (0–26%) [28, 37, 70, 72, 74, 75]. The weighted mean prevalence of masked hypertension, available from six studies, was 14.3 ± 11.9% (Table 5) [28, 37, 70, 72, 74, 75]. It has to be underlined that the high proportion of masked hypertension cases could have been overestimated, as it has previously been shown that many patients with masked hypertension become normotensive at a second ABPM [86]. On the other hand, the identification of masked hypertension is considered important, as some studies have shown a similar left ventricular mass index in subjects with either masked or sustained hypertension [81]. However, no studies relating ABPM levels to outcomes such as myocardial infarction or stroke are currently available for the pediatric population [81].

We recommend that ABPM be performed in children with CSK and office BP > 95th percentile to determine whether sustained hypertension or white coat hypertension exists. As
Table 6  Reported risk factors for an adverse renal outcome in subjects with CSK

| Author, year | Age | Outcome | Absence of compensatory enlargement | CAKUT (spontaneous) | UTI | Baseline creatinine | Baseline eGFR | Proteinuria | Hypertension | Hematuria | Age | Family History of CAKUT | Low Birth weight | Birth length | Prenatal diagnosis | Body mass index | Diabetic Mellitus | Uric Acid | RAS blockade | Duration of follow-up | Extra-renal anomalies | Gender | Phenotype | Prematurity | Side |
|--------------|-----|---------|-------------------------------------|---------------------|-----|---------------------|---------------|-------------|-------------|----------|-----|------------------------|-----------------|--------------|-------------------|----------------|----------------|----------|-------------|------------------|-------------------|--------|----------|------------|------|
| Mansoor (2011) | C | eGFR < 90 ml/min/1.73 m² | 8/82 (9.7%) | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Westland (2013) | C | KI 68/223 (31%) | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Kebloch (2016) | C | K I 29/27 (33.3%) | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| La Scola (2016) | C | eGFR < 90 ml/min/1.73 m² | 3/27 (11.1%) | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Marruffo (2017) | C | K I 12/66 (3.9%) | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Ursarri (2017) | C | eGFR < 90 ml/min/1.73 m² | 18/146 (12%) | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Poggi (2019) | C | K I 18/62 (11.1%) | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Wang (2010) | A | mGFR < 60 ml/min/1.73 m² | 25/65 (38%) | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Bachturk (2019) | A | eGFR < 40 ml/min/1.73 m² | 14/18 (44%) | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Xu (2019) | A | eGFR < 60 ml/min/1.73 m² | 30/38 (25.4%) | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |

White boxes correspond to not analyzed risk factors, + : significant at univariate analysis, + + : significant at multivariate analysis when performed; *includes also cohorts described in reference 33; **includes also patients described in reference 23

Legend: CSK congenital solitary kidney, C children, A adults, eGFR estimated glomerular filtration rate, KI kidney injury, mGFR measured glomerular filtration rate, NR not reported, ns not significant, CAKUT congenital anomalies of kidney and urinary tract, UTI urinary tract infection, RAS renin angiotensin system
for the detection of masked hypertension, we believe that it should not be part of a routine screening in all children with a CSK and normal office BP, until more data become available on the clinical benefits of screening. On the other hand, ABPM should be considered in children in whom the CSK is associated with other high-risk conditions for hypertension, known for the general pediatric population, i.e., CKD grade ≥ II, a history of prematurity or obesity [87].

Statements/recommendations:

1. We do not recommend routine ABPM in children with a CSK and normal office BP (grade C).
2. We recommend ABPM in children with a CSK, who are older than 5 years, with office BP > 95th percentile (grade C).
3. We recommend that ABPM be strongly considered in children in whom the CSK is associated with other high-risk conditions for hypertension (i.e., CKD grade ≥ II, a history of prematurity or obesity) (grade C).

Can kidney protective medication be used safely in CSK?

Renin–angiotensin–aldosterone system (RAAS) inhibitors provide a clear kidney protective advantage in the progression of disease due to their ability to control hypertension and reduce proteinuria, whose proposed effects on the kidney include increased glomerulosclerosis, tubulointerstitial inflammation, and fibrosis, thereby contributing to progressive kidney function loss. Treatment with RAAS inhibitors, which decreases filtered proteins, also decreases the production of inflammatory cytokines and preserves kidney function [88]. Notwithstanding, in a retrospective study on children with bilateral hypodysplastic kidneys, treating or not with angiotensin converting enzyme inhibitors did not significantly modify the decline of kidney function [89]. Furthermore, the few studies that tested the impact of RAAS inhibitors on the function of solitary kidneys were mainly conducted in animals and only limited data have been reported for humans [90]. In a study involving 16 adults, no beneficial effects were found in terms of the progression of kidney failure [39]. Thus, this therapeutic approach in CSK remains controversial [90]. Notwithstanding, RAAS inhibitors in CSK can be indicated when signs of kidney damage progression are documented [3, 4, 21, 91] remembering that, in the infant, angiotensin inhibition can impair maturation of the kidney, exacerbate sodium wasting, and markedly reduce GFR [92]. Conversely, angiotensin inhibition is contraindicated in patients with arterial stenosis of the solitary kidney, due to the high risk of developing acute kidney injury [93]. An acute rise in serum creatinine, which should not exceed 25%, is expected after the start of RAAS inhibition [94]. Therefore, creatinine should be checked 3–4 weeks after starting treatment and the dose of RAAS inhibitors reduced or treatment withdrawn if creatinine increases > 25%. Moreover, the usual safety precautions for the use of these medications have to be considered.

Statements/recommendations:

1. RAAS inhibitors should be used with caution in infants with a CSK (grade C).
2. RAAS inhibitors can be used beyond infancy to control hypertension and/or reduce proteinuria in children with CSK (grade C).
3. RAAS inhibitors must be avoided in patients with arterial stenosis of the solitary kidney (grade C).

Which nutritional and lifestyle habits should be adopted for children with a CSK?

Children with a CSK showing compensatory enlargement and with normal BP should follow the same nutritional principles as the general pediatric population, and dietary recommendations issued for healthy children and adolescents [95] can serve as a guide; moreover, the importance of avoiding obesity and its long term consequences should be kept in mind [96]. The benefits of a low protein diet, which has often been advocated as useful in preserving kidney function in subjects with a reduced nephron number, have never been demonstrated in subjects with a solitary kidney [97]. On the other hand, it has to be remembered that in the Western world, protein intake is usually higher than recommended [98]. Therefore, avoiding the excessive protein intake so common in Western society is recommended in children with a CSK. As regards salt intake, various surveys and trials have demonstrated a very high intake by children in the Western world, and there is strong evidence to suggest that a high intake plays an important role in the genesis of hypertension and target organ damage [99]. For these reasons, excessive salt intake must be avoided in children with a CSK, remembering that table salt only represents approximately 10% of the daily intake, the greatest amount being contained in processed foods [99].

As in children with two kidneys, normal hydration should be guaranteed at all times, and in particular during sport activities, as a small-volume fluid intake, although not altering kidney function, is associated with an increased risk of urolithiasis and UTI [100].

Additional risk factors for kidney damage, including nephrotoxic drugs, should be avoided or minimized [21, 92]. In this respect, we suggest that acetaminophen be used to reduce fever and to relieve pain, thus avoiding the use of non-steroidal anti-inflammatory drugs.
### Table 7: Prevalence of hypertension and abnormal dipping in children with congenital solitary kidney at ambulatory blood pressure monitoring

| Author, year | N | Age at ABPM (yrs) | Compensatory enlargement* | Ipsilateral CAKUT eGFR < 90 ml/min/1.73 m² | OBP hypertension | ABPM hypertension | Masked hypertension | WCH | Abnormal dipping |
|--------------|---|--------------------|----------------------------|---------------------------------|------------------|-------------------|---------------------|-----|----------------|
| Seeman T. (2001) [70] | 25 | 7.8 (3.8–17.7) | 21/25 (84%) | 4/25 (16%) | 2/25 Mean eGFR 55, 23/25 Mean eGFR 110, range 85–159 | 8/25 (33%) | 5/25 (20%) | 1/25 (4%) | 4/25 (16%) | 5/25 (20%) |
| Mei-Zahav M. (2001) [85] | 18 | 9.6 ± 3.9 | 18/18 (100%) | 0/18 | 0/18 | NR | NR | NR | NR | 0/18 |
| Seeman T. (2006) [28] | 15 | 10.0 (4–17) | 13/15 (87%) | 0/15 | 0/15 | 5/15 (33%) | 1/15 (7%) | 0/15 | 4/15 (26%) | 2/15 (14%) |
| Dursun H. (2007) [71] | 44 | 8.3 ± 4.2 | NR | 0/44 | 0/44 | NR | 10/44 (23%) | NR | NR | 13/44 (29.5%) |
| Westland R. (2014) [72] | 28 | 12.5 ± 3.6 | 24/28 (86%) | NR | 0/28 | 2/28 (7%) | 7/28 (25%) | 5/28 (18%) | 0/28 | 8/28 (29%) |
| Tabel Y. (2015) [73] | 44 | 10.9 ± 3.3 | NR | NR | 0/44 | NR | 19/44 (43%) | NR | NR | NR |
| Lubrano R. (2017) [74] | 38 | About 14.5 | NR | Scars 24/38 (63%) | Mean eGFR 103 ± 46 | 11/38 (29%) | 11/38 (29%) | 0/38 | 0/38 | NR |
| Zambaiti E. (2018) [32] | 50 | 9.5 ± 4.2 | 39/50 (78.5%) | NR | Mean eGFR 80 ± 12 | 10/50 (20%)** | 23/50 (46%)*** | NR | NR | 41/50 (82%) |
| La Scola C. (2020) [37] | 81 | 11.8 ± 4.7 | NR | 9/50 (18%) | 0/81 | 13/81 (16%) | 27/81 (33.3%) | 21/81 (25.9%) | 7/81 (8.6%) | 51/81 (64%) |
| Kasap-Demir B. (2021) [75] | 36 | 11 ± 4.75 | NR | 0/36 | 1/36 (3%) | Mean eGFR 127 ± 19.85 | 10/36 (28%) | 7/36 (19%) | 5/36 (14%) | 8/36 (22%) | NR |

*Kidney length ≥ 2DS for age or ≥ 95th percentile for height; **patients with elevated blood pressure defined as mean systolic and/or diastolic office blood pressure ≥ 90th but < 95th percentile; ***patients with either 24-h hypertension (ABPM values ≥ 95th percentile) or elevated blood pressure (ABPM values ≥ 90th but < 95th percentile)

**Legend:** ABPM ambulatory blood pressure monitoring, CAKUT congenital anomalies of kidney and urinary tract, eGFR estimated glomerular filtration rate, OBP office blood pressure, WCH white coat hypertension, NR not reported
Pediatric Nephrology (2022) 37:2185–2207

Statements/recommendations:

1. We recommend that in children with a CSK, protein intake should follow the dietary recommendations for children of the same age and sex, avoiding the excessive protein intake which is common in Western society (grade B).
2. We recommend that in children with a CSK, salt intake should follow the dietary recommendations for children of the same age and sex, avoiding the excessive salt intake which is common in Western society (grade B).
3. We recommend that dehydration be avoided, and regular fluid intake be encouraged, in particular during sport activities (grade C).
4. We recommend that the use of nephrotoxic drugs be avoided or minimized (grade C).

Can sports be played without restraint by subjects with a CSK?

Whether or not children with a solitary kidney can play the same sports as their peers has been a matter of extensive debate. In that debate, it emerged that the majority of severe kidney injuries are not sport related, but due to road accidents or falls [101, 102]. Furthermore, various reports have highlighted that sport-related kidney injuries are very rare [101–105]. A literature search of papers published between 1966 and 2005 found an incidence of catastrophic sports-related kidney injury of 0.4 per 1 million children per year for all sports, the kidney being much less involved than other vital organs, such as the brain and spinal cord, which are also single organs [103]. In school athletes, kidney trauma was found to occur significantly less often than other organ-specific injuries: in the National Athletic Trainers’ Association registries 1995–1997, out of 4.4 million athlete exposures, 18 (0.07%) kidney injuries were identified, none of which led to genitourinary surgery or kidney loss [104]. A recent review of trauma data observed that “limited-contact” sports like skiing, snowboarding, sledding, biking, and horseback riding are more often associated with high-grade injury and kidney loss than contact sports like football [106]. The most common sports that can cause severe kidney injury are related to collision: sledding, skiing, snowboarding, cycling, rollerblading, and contact sports; equestrian activities can also be associated with kidney trauma [101–103].

As regards the use of protective equipment during sports, there is no evidence to suggest its efficacy in the prevention of kidney injury [107].

Policy statements have been issued on sports participation for children with solitary kidneys. In the latest American Academy of Pediatrics statement on sports in different medical conditions, it was observed that, for the majority of chronic health conditions, available evidence supports the participation of children and adolescents in most athletic activities [108]. For children with a solitary kidney, no restrictions on noncontact sports, and individual assessment for limited-contact, contact/collision sports was suggested. The use of protective equipment was encouraged. The Canadian Urological Association Best Practice Report on sports and the solitary kidney [107] supported the 2008 American Academy of Pediatrics policy statement. It also stated that caregivers should be informed about the sports that carry a higher risk of kidney injury, but also that they should be encouraged to remember that the activities most associated with high-grade kidney trauma have a much higher risk of head injury.

Statements/recommendations:

1. We recommend that sport participation should not be restricted in children with CSK (grade B).
2. Caregivers and children should be informed that some sports, particularly if at risk of collision, (like cycling, sledding, downhill skiing/snowboarding, rollerblading, equestrian activities, and some contact sports) may carry a higher risk of kidney trauma than other activities (grade B) and that the use of flank protectors remains debated (grade C).

What follow-up for children with a CSK?

Congenital solitary kidney has an impact on the entire life cycle. However, the understanding of its natural history is still incomplete: therefore, we provide our recommendations with the caveat that strong evidence on the risks of long-term complications is lacking.

As the absence of compensatory enlargement of the CSK and the presence of associated CAKUT appear important risk factors for progressive kidney damage, we propose that, following the assessment previously described, the follow-up schedule be based on risk stratification, as follows:

- low risk: kidney length > 50th percentile in the first 2 years of life and ≥ 95th percentile thereafter, and absence of ipsilateral CAKUT
- medium risk: CSK without compensatory enlargement, and/or with an ipsilateral CAKUT
- high risk: decreased eGFR (i.e., mean eGFR for age – 1 SD in children younger than 2 years, < 90 ml/min/1.73 m² in children older than 2 years) and/or proteinuria, and/or hypertension.

In our opinion, children at low risk can be followed by general pediatricians (provided it is feasible on the
Table 8 Opinion-based recommendations for follow-up in children and adolescents with congenital solitary kidney

|                      | Low risk* | Medium risk* | High risk* |
|----------------------|-----------|--------------|------------|
|                      | Without CAKUT | With ipsilateral CAKUT | Pediatric nephrology unit |
| **Setting**          | Primary pediatric care | Pediatric nephrologist/pediatric nephrology unit | Pediatric nephrology unit |
| **Ultrasound** ^2     | Yearly until 3 years of age, then every 5 years | Yearly until 3 years of age, then every 3 to 5 years | Further work-up depending on additional ipsilateral CAKUT findings |
| **Proteinuria by urinalysis** ^3 | Yearly until 3 years of age, then every 5 years | Yearly | According to kidney function and clinical data |
| **Office Blood pressure** | Yearly | Yearly | Yearly |
| **Serum creatinine/eGFR** | Not necessary | Not necessary | Not necessary |
| **Abdominopelvic ultrasound in girls** | Between thelarche and menarche | Between thelarche and menarche | Between thelarche and menarche |

---

- **Risk stratification:**
  - Low risk: kidney length > 50th percentile in the first 2 years of life and ≥ 95th percentile thereafter, and absence of ipsilateral CAKUT
  - Medium risk: CSK without compensatory enlargement, and/or with an ipsilateral CAKUT
  - High risk: decreased eGFR (i.e., mean eGFR for age - 1 SD in children younger than 2 years, < 90 ml/min per 1.73 m² in children older than 2 years) and/or proteinuria, and/or hypertension

1. As feasible according to the organization of the local health care system; 2. With measurement of kidney length/size; 3. If proteinuria is detected, quantification by urine protein/urine creatinine should be performed in the second morning urine sample, remembering that normal values are < 0.5 mg/mg until two years of age and < 0.2 thereafter

**Legend:** CAKUT congenital anomalies of kidney and urinary tract, eGFR estimated glomerular filtration rate
basis of the local health care system), while children at medium risk, who need specialist surveillance, should be under the care of a pediatric nephrologist, and those at high risk should be followed in pediatric nephrology units. The type and timing of the recommended check-ups are reported in Table 8. In all the risk classes, females must undergo an abdominopelvic US after thelarche and before menarche, for the evaluation of the genital apparatus. Moreover, in all the risk classes, follow-up must be continued during adolescence. Finally, the transition of patients from pediatric to adult healthcare providers has to be accurately planned, as it represents a critical period in terms of maintaining kidney function [92].

**Statements/recommendations:**

1. We recommend that all children with a CSK be followed until adulthood as outlined in Table 8, according to risk stratification (grade B).

2. We suggest that children at low risk should be followed by general pediatricians, provided it is feasible on the basis of the local health care system, while children at medium risk should be under the care of a pediatric nephrologist and children at high risk be followed in pediatric nephrology units (grade C).

**Health benefits, limitations of our recommendations and future perspectives**

This consensus statement provides guidance on the initial diagnostic work-up, the nutritional and lifestyle habits, and the follow-up of children with CSK.

We believe that health benefits are obtained by a reduction of the number of VCUG and nuclear scans performed, therefore decreasing radiation exposure and financial costs. Another benefit may be gained by restricting the prescription of laboratory blood testing.

Our recommendations are not without limitations. First, available evidence to support most of these recommendations comes from retrospective cohort studies, because randomized clinical trials or prospective studies with consistent and good-quality patient-oriented evidence are lacking. Second, this is a consensus statement developed by pediatric nephrologists; other specialists may have different opinions. However, these recommendations can be used for comparison with other available indications and protocols, as a worldwide consensus in this area is lacking.

The authors of these recommendations have found some gaps in our knowledge about CSK:

- second, further studies are needed to validate a risk stratification model applicable early in life, to tailor follow-up accordingly;
- third, the presence, degree, and time course of hyperfiltration in human CSK and its influence on subsequent kidney injury should be studied.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00467-022-05528-y.

Acknowledgements The authors thank Alexandra Teff for providing linguistic advice and Giuseppe Puccio, MD, for help in statistical analysis.

Availability of data and material Data obtained from the literature.

Code availability NA.

**Declarations**

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Schreuder MF, Westland R, Van Wijk JAE (2009) Unilateral multicystic dysplastic kidney: a meta-analysis of observational studies on the incidence, associated urinary tract malformations and the contralateral kidney. Nephrol Dial Transplant 24:1810–1818. https://doi.org/10.1093/ndt/gfn777

2. Westland R, Schreuder MF, Ket JCF, Van Wijk JAE (2013) Unilateral renal agenesis: a systematic review on associated anomalies and renal injury. Nephrol Dial Transplant 28:1844–1855. https://doi.org/10.1093/ndt/gft012

3. Woolf AS, Hillman KA (2007) Unilateral renal agenesis and the congenital solitary functioning kidney: developmental, genetic and clinical perspectives. BJU Int 99:17–21. https://doi.org/10.1111/j.1464-410X.2006.06504.x

4. Vu KH, Van Dyck M, Daniels H, Proesmans W (2008) Renal outcome of children with one functioning kidney from birth. A study of 99 patients and a review of the literature. Eur J Pediatr 167:885–890. https://doi.org/10.1007/s00431-007-0612-y

5. Corbani V, Ghiggeri GM, Sanna-Cherchi S (2011) Congenital solitary functioning kidneys: which ones warrant follow-up into adult life? Nephrol Dial Transplant 26:1458–1460. https://doi.org/10.1093/ndt/gfr145
6. Westland R, Schreuder MF, van Goudoever JB, Sanna-Cherchi S, van Wijk JAE (2014) Clinical implications of the solitary functioning kidney. Clin J Am Soc Nephrol 9:978–986. https://doi.org/10.2215/CJN.08900813
7. La Scola C, Ammenti A, Puccio G, Lega ML et al (2016) Congenital solitary kidney in children: size matters. J Urol 196:1250–1256. https://doi.org/10.1016/j.juro.2016.03.173
8. Schreuder MF (2018) Life with one kidney. Pediatr Nephrol 33:595–604. https://doi.org/10.1007/s00467-017-3685-4
9. Groenink Woud S, Westland R, Feitz WJF, Roeleveld N et al (2021) Clinical management of children with a congenital solitary functioning kidney: overview and recommendations. Eur Urol Open Sci 25:11–20. https://doi.org/10.1016/j.euros.2021.01.003
10. Ebell MH, Siwek J, Weiss BD, Woolf SH et al (2004) Strength of Recommendation Taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician 69:548–556. https://doi.org/10.3122/jabfm.17.1.59
11. Scharding C, Adams MB, Owens T, Keitz S, Fontelo P (2007) Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak 7. https://doi.org/10.1186/1472-6947-7-16
12. Oh KY, Holznagel DE, Ameli JR, Sohaey R (2010) Prenatal diagnosis of renal developmental anomalies associated with an empty renal fossa. Ultrasound Q 26:233–240. https://doi.org/10.1097/RUQ.0b013e3181f731fd
13. Van Vuure SH, Van Der Doet R, Cohen-Overbeek TE, Goldschmeding R et al (2012) Compensatory enlargement of a solitary functioning kidney during fetal development. Ultrasound Obstet Gynecol 40:665–668. https://doi.org/10.1002/uog.11168
14. Wiesel A, Queisser-Luft A, Clementi M, Bianca S et al (2005) Prenatal detection of congenital renal malformations by fetal ultrasonographic examination: an analysis of 709,030 births in 12 European countries. Eur J Med Genet 48:131–144. https://doi.org/10.1016/j.medj.2005.02.003
15. Whittam BM, Calaway A, Szymanski KM, Carroll AE et al (2014) Ultrasound diagnosis of multicystic dysplastic kidney: is a confirmatory nuclear medicine scan necessary? J Pediatr Urol 10:1059–1062. https://doi.org/10.1016/j.jpurol.2014.03.011
16. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics, Society for Maternal-Fetal Medicine Committee on Genetics (2016) Practice Bulletins No. 162: Prenatal Diagnostic Testing for Genetic Disorders. Obs Gynecol 127:e108–e122
17. Ursari A, Gil M, Mandià N, Aldamiz-Echevarría L et al (2018) Retrospective study to identify risk factors for chronic kidney disease in children with congenital solitary functioning kidney detected by neonatal renal ultrasound screening. Med 97:e11819. https://doi.org/10.1016/j.md.2018.e000011819
18. Krill A, Cubillos J, Gitlin J, Palmer LS (2012) Abdominopelvic ultrasound: a cost-effective way to diagnose solitary kidney. J Urol 187:2201–2204. https://doi.org/10.1016/j.juro.2012.01.129
19. Morin CE, Mcbee MP, Trout AT, Reddy PP, Dillman JR (2018) Use of MR urography in pediatric patients. Curr Urol Rep 19:93
20. Shaikh N, Spingarn RB, Hum SW (2016) Dimercaptosuccinic acid scan or ultrasound in screening for vesicoureteral reflux among children with urinary tract infections. Cochrane Database Syst Rev 7(7). https://doi.org/10.1002/14651858.CD010657.PUB2
21. Cochat P, Febve Y, Bacchetta J, Bérard E et al (2019) Towards adulthood with a solitary kidney. Pediatr Nephrol 34:2311–2323. https://doi.org/10.1007/s00467-018-4085-1
22. Weinstein A, Goodman TR, Iragorri S (2008) Simple multicystic dysplastic kidney disease: end points for subspecialty follow-up. Pediatr Nephrol 23:111–116. https://doi.org/10.1007/s00467-007-0635-7
23. Marzuollo P, Guarino S, Grandone A, Di Somma A et al (2019) Congenital solitary kidney size at birth could predict reduced eGFR levels later in life. J Perinatol 39:129–134. https://doi.org/10.1038/s41372-018-0260-2
24. Rosenbaum DM, Korgold E, Teele RL (1984) Sonographic assessment of renal length in normal children. Am J Roentgenol 142:467–469. https://doi.org/10.2214/ajr.142.3.467
25. Dinkel E, Ertel M, Dittrich M, Peters H et al (1985) Kidney size in childhood Sonographical growth charts for kidney length and volume. Pediatr Radiol 15:38–43. https://doi.org/10.1007/BF02387581
26. Chen JH, Zhi J, Mao W, Steinhardt GF (2006) MrNomogram: a web-based multivariable pediatric renal nomogram. J Pediatr Urol 2:436–438. https://doi.org/10.1016/j.jpurol.2005.10.003
27. Abidari JM, Park KH, Kennedy WA, Shortlife LD (2002) Serial followup of the contralateral renal size in children with multicystic dysplastic kidney. J Urol 168:1821–1825. https://doi.org/10.1016/S0022-5347(05)04422-9
28. Seeman T, Patzer L, John U, Dušek J et al (2006) Blood pressure, renal function, and proteinuria in children with unilateral renal agenesis. Kidney Blood Press Res 29:210–215. https://doi.org/10.1159/000095735
29. Schreuder MF, Langemeijer ME, Böenkamp A, Delemarre-Van de Waal HA, Van Wijk JAE (2008) Hypertension and microalbuminuria in children with congenital solitary kidneys. J Paediatr Child Health 44:363–368. https://doi.org/10.1111/j.1440-1754.2008.01315.x
30. Hayes WN, Watson AR (2012) Unilateral multicystic dysplastic kidney: does initial size matter? Pediatr Nephrol 27:1335–1340. https://doi.org/10.1007/s00467-012-2141-9
31. Marzuollo P, Guarino S, Grandone A, Di Somma A et al (2017) Outcomes of a cohort of prenatally diagnosed and early enrolled patients with congenital solitary functioning kidney. J Urol 198:1153–1158. https://doi.org/10.1016/j.juro.2017.05.076
32. Zambaiti E, Sergio M, Baldanza F, Corrado C et al (2019) Correlation between hypertrophy and risk of hypertension in congenital solitary functioning kidney. Pediatr Surg Int 35:167–174. https://doi.org/10.1007/s00383-018-4389-z
33. Westland R, Schreuder MF, Böenkamp A, Spreeuwenberg MD, van Wijk JAE (2011) Renal injury in children with a solitary functioning kidney—the KIMONO study. Nephrol Dial Transplant 26:1533–1541. https://doi.org/10.1093/ndt/gfsq444
34. Mansoor O, Chandar J, Rodriguez MM, Abitbol CL et al (2011) Long-term risk of chronic kidney disease in unilateral multicystic dysplastic kidney. Pediatr Nephrol 26:597–603. https://doi.org/10.1007/s00467-010-1746-0
35. Cachet F, Combescure C, Chehade H, Zieier G et al (2013) Microalbuminuria and hyperfiltration in subjects with nephrop-urological disorders. Nephrol Dial Transplant 28:386–391. https://doi.org/10.1093/ndt/gfs494
36. Shirzai A, Yildiz N, Biyikli N, Ustunsoy S et al (2014) Is microalbuminuria a risk factor for hypertension in children with solitary kidney? Pediatr Nephrol 29:283–288. https://doi.org/10.1007/s00467-013-2641-2
37. La Scola C, Marra G, Ammenti A, Pasini A et al (2020) Born with a solitary kidney: at risk of hypertension. Pediatr Nephrol 35:1483–1490. https://doi.org/10.1007/s00467-020-04535-1
38. Wang Y, Wang Z, Wang W, Ren H et al (2010) Analysis of factors associated with renal function in Chinese adults with congenital solitary kidney. Intern Med 49:2203–2209. https://doi.org/10.2169/internalmedicine.49.3742
39. Basturk T, Koc Y, Ucar Z, Sakaci E et al (2015) Renal damage frequency in patients with solitary kidney and factors that affect progression. Int J Nephrol 2015:876907. https://doi.org/10.1155/2015/876907
40. Zerin JM, Blane CE (1994) Sonographic assessment of renal length in children: a reappraisal. Pediatr Radiol 24:101–106. https://doi.org/10.1007/BF02020164

41. Blachman-Braun R, Camp MM, Becerra MF, Christian G et al (2020) Voiding cysotourethrogram in children with unilateral multicystic dysplastic kidney: is it still necessary? Urology 139:156–160. https://doi.org/10.1016/j.urology.2020.02.005

42. Ross I, Ahn HJ, Roelof B, Barber T et al (2015) Sonographic assessment of the effect of vesicoureteral reflux and urinary tract infections on growth of the pediatric solitary kidney. J Pediatr Urol 11:145.e1-145.e6. https://doi.org/10.1016/j.jpurol.2015.02.012

43. Brown C, McLeod D, Ching C (2019) Knowledge of vesicoureteral reflux obtained by screening voiding cysotourethrogram in children with multicystic dysplastic kidney does not change patient management or prevent febrile urinary tract infection. J Pediatr Urol 15:267.e1-267.e5. https://doi.org/10.1016/j.jpurol.2019.03.013

44. Ammenti A, Alberici I, Brugnara M, Chimenz R et al (2020) Updated Italian recommendations for the diagnosis, treatment and follow-up of the first febrile urinary tract infection in young children. Acta Paediatr 109:236–247. https://doi.org/10.1111/apa.14988

45. Garin EH (2019) Primary vesicoureteral reflux: what have we learnt from the recently published randomized, controlled trials? Pediatr Nephrol 34:1513–1519. https://doi.org/10.1007/s00467-018-4045-9

46. Yamamoto K, Kamei K, Sato M, Ogura M et al (2018) Necessity of performing voiding cysotourethrogram for children with unilateral multicystic dysplastic kidney. Pediatr Nephrol 34:295–299. https://doi.org/10.1007/s00467-018-4079-Z

47. Shaheen IS, Watson AR, Broderick N, Rance C (2005) Multicystic dysplastic kidney and pelviureteric junction obstruction. Pediatr Surg Int 21:456–459. https://doi.org/10.1007/s00059-005-0140-8

48. Poggioli IV, Simões e Silva AC, Vasconcelos MA, Dias CS et al (2019) A clinical predictive model of renal injury in children with congenital solitary functioning kidney. Pediatr Nephrol 34:465–474. https://doi.org/10.1007/s00467-018-4111-3

49. Hogg RJ, Furth S, Lemley KV, Portman R et al (2003) National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative, National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 111:1416–1421. https://doi.org/10.1542/peds.111.6.1416

50. Groen in ‘t Woud S, Renkema KY, Schreuder MF, Wijers CHW et al (2016) Maternal risk factors involved in specific congenital anomalies of the kidney and urinary tract: a case–control study. Birth Defects Res Part A Clin Mol Teratol 106:596–603. https://doi.org/10.1002/bdra.23500

51. Friedman MA, Aguilar L, Heyward Q, Wheeler C, Caldame A (2018) Screening for Mullerian anomalies in patients with unilateral renal agenesis: leveraging early detection to prevent complications. J Pediatr Urol 14:144–149. https://doi.org/10.1016/j.jpurol.2018.01.011

52. Dursun H, Bayazit AK, Büyükcüelik M, Soran M et al (2005) Associated anomalies in children with congenital solitary functioning kidney. Pediatr Surg Int 21:456–459. https://doi.org/10.1007/s00467-005-1408-7

53. Acién P, Acién M (2016) The presentation and management of complex female genital malformations. Hum Reprod Update 22:48–69. https://doi.org/10.1093/humupd/dmv048

54. Heidt L, Morinière V, Henry C, De Tomasi L et al (2017) Targeted exome sequencing identifies PBX1 as involved in monogenic congenital anomalies of the kidney and urinary tract. J Am Soc Nephrol 28:2901–2914. https://doi.org/10.1681/ASN.2017040043

55. Wu H, Xu Q, Xie J, Ma J et al (2017) Identification of 8 novel mutations in nephrogenesis-related genes in Chinese Han patients with unilateral renal agenesis. Am J Nephrol 46:55–63. https://doi.org/10.1159/000477590

56. Ishiwa S, Sato M, Morisada N, Nishi K, Kanamori T et al (2019) Association between the clinical presentation of congenital anomalies of the kidney and urinary tract (CAKUT) and gene mutations: an analysis of 66 patients at a single institution. Pediatr Nephrol 34:1457–1464. https://doi.org/10.1007/s00467-019-04230-w

57. van der Ven AT, Connaughton DM, Ijtel H, Mann N et al (2018) Whole-exome sequencing identifies causative mutations in families with congenital anomalies of the kidney and urinary tract. J Am Soc Nephrol 29:2348–2361. https://doi.org/10.1681/ASN.2017121265

58. Westland R, Renkema KY, Knoers NVAM (2020) Clinical integration of genome diagnostics for congenital anomalies of the kidney and urinary tract. Clin J Am Soc Nephrol 16:128–137. https://doi.org/10.2215/CJN.14661119

59. Bertram JF, Douglas-Denton RN, Diouf B, Hughson MD et al (2011) Human nephron number: Implications for health and disease. Pediatr Nephrol 26:1529–1533. https://doi.org/10.1007/s00467-011-1843-8

60. Maluf NSR (1997) On the enlargement of the normal congenital solitary kidney. BJ Urol 79:836–841. https://doi.org/10.1016/j.urology.2017.10.046/s0164-110x(97)00215-x

61. Brenner BM, Lawler EV, Mackenzie HS (1996) The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 49:1774–1777. https://doi.org/10.1038/kj.1996.265

62. Abou Jaoudé P, Dubourg L, Bacchetta J, Berthiller J et al (2011) Congenital versus acquired solitary kidney: is the difference relevant? Nephrol Dial Transplant 26:2188–2194. https://doi.org/10.1093/ndt/gfq659

63. Stefanowicz J, Owczuk R, Kaużyńska B, Aleksandrowicz E et al (2012) Renal function and solitary kidney disease: Wilms tumour survivors versus patients with unilateral renal agenesis. Kidney Blood Press Res 35:174–181. https://doi.org/10.1159/000322083

64. Westland R, Kurvers RAJ, Van Wijk JAE, Schreuder MF (2013) Risk factors for renal injury in children with a solitary functioning kidney. Pediatrics 131:e478–485. https://doi.org/10.1542/peds.2012-20888

65. Kolvek G, Podracka L, Rosenberger J, Stewart RE et al (2014) Solitary functioning kidney in children — a follow-up study. Kidney Blood Press Res 39:272–278. https://doi.org/10.1159/000355804

66. Siomou E, Giapros V, Papadopoulou F, Pavlou M et al (2014) Growth and function in childhood of a normal solitary kidney from birth or from early infancy. Pediatr Nephrol 29:249–256. https://doi.org/10.1007/s00467-013-2623-4

67. Argueso LR, Ritchey ML, Boyle ET Jr, Milliner DS, Bergstralh EJ, Kramer SA (1992) Prognosis of patients with unilateral renal agenesis. Pediatr Nephrol 6:412–416. https://doi.org/10.1007/BF00873996

68. Sanna-Cherchi S, Ravani P, Corbani V, Parodi S, Haupt R et al (2009) Renal outcome in patients with congenital anomalies of the kidney and urinary tract. Kidney Int 76:528–533. https://doi.org/10.1038/ki.2009.220

69. Xu Q, Wu H, Zhou L, Xie J et al (2019) The clinical characteristics of Chinese patients with unilateral renal agenesis. Clin Exp Nephrol 23:792–798. https://doi.org/10.1007/s10157-019-01704-x

70. Seeman T, John U, Bláhová K, Vondrichová H et al (2001) Ambulatory blood pressure monitoring in children with unilateral
multicystic dysplastic kidney. Eur J Pediatr 160:78–83. https://doi.org/10.1007/s0043100000579
71. Dursun H, Bayazit AK, Cengiz N, Seydaoglu G et al (2007) Ambulatory blood pressure monitoring and renal functions in children with a solitary kidney. Pediatr Nephrol 22:559–564. https://doi.org/10.1007/s00467-006-0389-7
72. Westland R, Schreuder MF, van der Loof DF, Vermeulen A et al (2014) Ambulatory blood pressure monitoring is recommended in the clinical management of children with a solitary functioning kidney. Pediatr Nephrol 29:2205–2211. https://doi.org/10.1007/s00467-014-2853-0
73. Tabel Y, Aksu O, Elmas AT, Çelik SF (2015) Evaluation of hypertension by ambulatory blood pressure monitoring in children with solitary kidney. Blood Press 24:119–123. https://doi.org/10.3109/08830705.2014.992194
74. Lubrano R, Gentile I, Falsaperla R, Vitaliti G et al (2017) Evolution of blood pressure in children with congenital and acquired solitary functioning kidney. Ital J Pediatr 43:1–6. https://doi.org/10.1186/s13052-017-0359-7
75. Kasap-Demir B, Soyaltin E, Arslanoyu-Çamlar S, Alparslan C et al (2021) Cardiovascular risk assessment in children and adolescents with congenital solitary kidneys. J Clin Hypertens 23:245–252. https://doi.org/10.1111/jch.14159
76. Luyckx VA, Brenner BM (2010) The clinical importance of nephron mass. J Am Soc Nephrol 21:899–910. https://doi.org/10.1681/ASN.2009121248
77. Parakh P, Bhatta NK, Mishra OP, Shrestha P et al (2012) Urinary screening for detection of renal abnormalities in asymptomatic school children. Nephrourol Mon 4:551–556. https://doi.org/10.5812/nmonthly.3528
78. Cho BS, Hahn WH, Cheong HI, Lim I, Ko CW et al (2013) A nationwide study of mass urine screening tests on Korean school children and implications for chronic kidney disease management. Clin Exp Nephrol 17:205–210. https://doi.org/10.1007/s10157-012-0672-9
79. Song P, Zhang Y, Yu J, Zha M et al (2019) Global prevalence of hypertension in children: a systematic review and meta-analysis. JAMA Pediatr 173:1154–1163. https://doi.org/10.1001/jamapediatrics.2019.3310
80. Narchi H (2005) Risk of hypertension with multicystic kidney disease: a systematic review. Arch Dis Child 90:921–924. https://doi.org/10.1136/adc.2005.07533
81. Flynn JT, Daniels SR, Hayman LL, Maahs DM et al (2014) Update: Ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. Hypertension 63:1116–1135. https://doi.org/10.1161/HYP.0000000000000007
82. Patel SS, Daniels SR (2019) Ambulatory blood pressure monitoring in pediatrics. Curr Hypertens Rep 21:71. https://doi.org/10.1007/s11906-019-0976-1
83. Soergel M, Kirschstein M, Busch C, Danne T et al (1997) Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: a multicenter trial including 1141 subjects. J Pediatr 130:178–184. https://doi.org/10.1016/S0022-3476(97)70340-8
84. Wüthi E, Witte K, Soergel M, Mehls O et al (2002) Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens 20:1995–2007. https://doi.org/10.1097/00043782-200210000-00019
85. Mei-Zahav M, Koretz Z, Cohen I, Kessler O et al (2001) Ambulatory blood pressure monitoring in children with a solitary kidney — a comparison between unilateral renal agenesis and uninephrectomy. Blood Press Monit 6:263–267. https://doi.org/10.1097/0126097-200110000-00007
86. Lurbe E, Torro I, Alvarez V, Navròt P, Paya R, Redon J, Staessen JA (2005) Prevalence, persistence, and clinical significance of masked hypertension in youth. Hypertension 45:493–498. https://doi.org/10.1161/01.HYP.0000163200.39303.ab
87. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D et al (2017) Subcommittee on Screening and Management of High Blood Pressure in Children Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 140:e20171904. https://doi.org/10.1542/peds. 2017-1904
88. Remuzzi G, Perico N, Macia M, Ruggenenti P (2005) The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int 68:57–65. https://doi.org/10.1111/j.1523-1755.2005.09911.x
89. Ardissino G, Viganò S, Testa S, Daccò V et al (2007) No clear evidence of ACEI efficacy on the progression of chronic kidney disease in children with hypophysplastic nephropathy — report from the ItalKid Project database. Nephrol Dial Transplant 22:2525–2530. https://doi.org/10.1093/ndt/gfm237
90. Simeoni M, Armeni A, Summaria C, Ceranontio A, Fuiano G et al (2017) Current evidence on the use of anti-raas agents in congenital or acquired solitary kidney. Ren Fail 39:660–670. https://doi.org/110.1080/0886022X.2017.1361840
91. Hegde S, Coulthard MG (2009) Renal agenesis and unilateral nephrectomy: what are the risks of living with a single kidney? Pediatr Nephrol 24:439–446. https://doi.org/10.1007/s00467-008-0924-9
92. Chevalier RL (2009) When is one kidney not enough? Kidney Int 76:475–477. https://doi.org/10.1038/ki.2009.244
93. Siddiqi N, Shatat IF (2020) Antihypertensive agents: a long way to safe drug prescribing in children. Pediatr Nephrol 35:2049–2065. https://doi.org/10.1007/s00467-019-04314-7
94. ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M et al (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:1639–1650. https://doi.org/10.1056/NEJMoa0902066
95. Gidding SS, Dennison BA, Birch LL, Daniels SR et al (2006) Dietary recommendations for children and adolescents: a guide for practitioners. Pediatrics 2:554–559. https://doi.org/10.1542/peds.2005-2565
96. La Scola C, Guarino S, Pasini A, Capalbo D et al (2020) Effect of body mass index on estimated glomerular filtration rate levels in children with congenital solitary kidney: a cross-sectional multicenter study. J Ren Nutr 30:261–267. https://doi.org/10.1053/j. jrn.2019.07.003
97. Tantisattamo E, Dafoe DC, Reddy Ug, Ichii H et al (2019) Current management of patients with acquired solitary kidney. Kidney Int Rep 4:1205–1218. https://doi.org/10.1016/j.ekir.2019.07.001
98. Halkjaer J, Olsen A, Bjerringaard LJ, Deharveng G et al (2009) Intake of total, animal and plant proteins, and their food sources in 10 countries in the European Prospective Investigation into Cancer and Nutrition. Eur J Clin Nutr 63:16–36. https://doi.org/10.1038/ejcn.2009.73
99. Ritz E, Mehls O (2009) Salt restriction in kidney disease — a missed therapeutic opportunity? Pediatr Nephrol 24:9–17. https://doi.org/10.1007/s00467-008-0856-4
100. Tack I (2010) Effects of water consumption on kidney function and excretion. Nutr Today 45:37–40. https://doi.org/10.1097/NT.0b013e3181fe4376
101. Johnson B, Christensen C, Dirusso S, Choudhury M et al (2005) A need for reevaluation of sports participation recommendations for children with a solitary kidney. J Urol 174:686–689. https://doi.org/10.1016/j.juro.2005.02.008
103. Grinsell MM, Showalter S, Gordon KA, Norwood VF (2006) Single kidney and sports participation: perception versus reality. Pediatrics 118:1019–1027. https://doi.org/10.1542/peds.2006-0663

104. Grinsell MM, Butz K, Gurka MJ, Gurka KK, Norwood V (2012) Sport-related kidney injury among high school athletes. Pediatrics 130:e40-45. https://doi.org/10.1542/peds.2011-2082

105. Brophy RH, Gamradt SC, Barnes RP, Powell JW et al (2008) Kidney injuries in professional American football: implications for management of an athlete with 1 functioning kidney. Am J Sports Med 36:85–90. https://doi.org/10.1177/0363546507308940

106. Papagiannopoulos D, Gong E (2017) Revisiting sports precautions in children with solitary kidneys and congenital anomalies of the kidney and urinary tract. Urology 101:9–14. https://doi.org/10.1016/j.urology.2016.11.025

107. Psooy K, Franc-Guimond J, Kiddoo D, Lorenzo A, MacLellan D (2019) Canadian Urological Association best practice report: Sports and the solitary kidney — what primary caregivers of a young child with a single kidney should know (2019 update). Can Urol Assoc J 13:315–317. https://doi.org/10.5489/cuaj.6118

108. Rice SG, American Academy of Pediatrics Council on Sports Medicine and Fitness (2008) Medical conditions affecting sports participation. Pediatrics 121:841–848. https://doi.org/10.1542/peds.2008-0080

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Claudio La Scola1 · Anita Ammenti2 · Cristina Bertulli1 · Monica Bodria3 · Milena Brugnara4 · Roberta Camilla5 · Valentina Capone6 · Luca Casadio7 · Roberto Chimenz8 · Maria L. Conte9 · Ester Conversano10 · Ciro Corrado11 · Stefano Guarino12 · Ilaria Luongo13 · Martino Marasci14 · Pierluigi Marzuillo12 · Davide Meneghesso15 · Marco Pennesi10 · Fabrizio Pugliese16 · Sara Pusceddu17 · Elisa Ravaio18 · Francesca Taroti6 · Gianluca Vergine9 · Licia Peruzzi5 · Giovanni Montini18

1 Pediatric Nephrology and Dialysis, Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Massarenti 11, 40138 Bologna, Italy
2 Pediatric Multi-Specialistic Unit, Poliambulatorio Medi-Saluser, Parma, Italy
3 Division of Nephrology, Dialysis, Transplantation, and Laboratory On Pathophysiology of Uremia, Istituto G. Gaslini, Genova, Italy
4 Pediatria C, Ospedale Donna Bambino, Verona, Italy
5 Pediatric Nephrology Unit, Regina Margherita Department, Azienda Ospedaliero-Universitaria Città Della Salute E Della Scienza, Torino, Italy
6 Pediatric Nephrology, Dialysis and Transplant Unit. Fondazione Ca’ Granda IRCCS, Policlinico Di Milano, Milano, Italy
7 Unità Operativa Complessa Di Nefrologia E Neonatologia, Ospedale Di Ravenna, AUSL Romagna, Ravenna, Italy
8 Unità Operativa Di Nefrologia Pediatrica Con Dialisi, Azienda Ospedaliero-Universitaria G. Martino, Messina, Italy
9 Department of Pediatrics, Infermi Hospital, Rimini, Italy
10 Institute for Maternal and Child Health—IRCCS Burlo Garofolo, Trieste, Italy
11 Pediatric Nephrology, “G. Di Cristina” Hospital, Palermo, Italy
12 Department of Woman, Child and of General and Specialized Surgery, Università Degli Studi della Campania “Luigi Vanvitelli, Napoli, Italy
13 Unità Operativa Complessa Di Nefrologia E Dialisi, AORN Santobono – Pausilipon, Napoli, Italy
14 Unità Operativa Di Pediatria E Terapia Intensiva Neonatale-Pediatrica, Ospedale M Bufalini, Cesena, Italy
15 Unità Operativa Complessa Di Nefrologia Pediatrica - Dialisi E Tranpianto, Dipartimento Di Salute Della Donna E del Bambino, Azienda Ospedaliero-Universitaria Di Padova, Padova, Italy
16 Pediatric Nephrology Unit, Department of Pediatrics, Marche Polytechnic University, Ancona, Italy
17 Pediatria AUSL, Imola, Italy
18 Giuliana and Bernardo Caprotti Chair of Pediatrics, Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy